Aesica Pharmaceuticals has entered agreements to acquire three manufacturing sites from UCB, in Monheim and Zwickau, Germany, and Pianezza, Italy. The acquisitions will nearly double the company’s capabilities in Europe and the staff across all the three sites will be maintained. Aesica has also entered a strategic partnership with UCB, consisting of a long-term supply agreement.

Dr. Robert Hardy, chief executive officer of Aesica, said, “The acquisition of the three UCB manufacturing sites is strategically crucial for our business as we extend and enhance our current offering and establish a presence in Europe. We hope to fully utilize the expertise and knowledge across the current team at the new sites to facilitate our continued expansion and to achieve our vision of becoming the leading supplier of API and formulated products to the global pharmaceutical and biotechnology industries.”

Aesica supplies contract development and contract manufacturing services for formulated products and APIs to pharma and biopharma companies globally.